Structure-based design of novel HIV protease inhibitors: Sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors

Journal of Medicinal Chemistry

Volumn 39, Issue 12, 1996, Pages 2400-2410

  Thaisrivongs, Suvit ^a   Janakiraman, Musiri N ^a   Chong, Kong Teck ^a   Tomich, Paul K ^a   Dolak, Lester A ^a   Turner, Steve R ^a   Strohbach, Joseph W ^a   Lynn, Janet C ^a   Horng, Miao Miao ^a   Hinshaw, Roger R ^a   Watenpaugh, Keith D ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY 2 PYRANONE DERIVATIVE; 4 HYDROXYCOUMARIN; AMIDE; N [3 [CYCLOPROPYL[4 HYDROXY 2 OXO 6 [1 (PHENYLMETHYL)PROPYL] 2H PYRAN 3 YL]METHYL]PHENYL] 1 METHYL 1H IMIDAZOLE 4 SULFONAMIDE; PHENPROCOUMON; PROTEINASE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; BILIARY EXCRETION; BINDING AFFINITY; CRYSTAL STRUCTURE; DIASTEREOISOMER; DRUG BIOAVAILABILITY; DRUG DESIGN; ENZYME BINDING; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

4-HYDROXYCOUMARINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HIV PROTEASE INHIBITORS; HIV-1; HIV-2; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHENPROCOUMON; PYRONES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 0029941361     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950888f     Document Type: Article

References (43)

1. Blundell, T. L.; Lapatto, R.; Wilderspin, A. F.; Hemmings, A. M.; Hobart, P. M.; Danley, D. E.; Whittle, P. J. The 3-D Structure of HIV-1 Protease and the Design of Antiviral Agents for the Treatment of AIDS. Trends Biol. Sci. 1990, 15, 425-430.
2. Debouck, C.; Metcalf, B. W. Human Immunodeficiency Virus Protease: A Target for AIDS Therapy. Drug. Dev. Res. 1990, 21, 1-17.
3. Huff, J. R. HIV Protease: A Novel Chemotherapeutic Target for AIDS. J. Med. Chem. 1991, 34, 2305-2314.
4. Meek, T. D. Inhibitors of HIV-1 Protease. J Enzyme Inhib. 1992, 6, 65-98.
5. Robins, T.; Plattner, J. HIV Protease Inhibitors: Their Anti-HIV Activity and Potential Role in Treatment. J. AIDS 1993, 6, 162-170.
6. Thaisrivongs, S. Chapter 14. HIV Protease Inhibitors. Annu. Rep. Med. Chem. 1994, 29, 133-144.
7. Plattner, J. J.; Norbeck, D. W. Chapter 5. Obstacles to Drug Development from Peptide Leads. In Drug Discovery Technologies; Clark, C. R., Moos, W. H., Eds.; Ellis Horwood Ltd.: Chichester, 1990; pp 92-126.
8. Martin, J. A. Recent Advances in the Design of HIV Protease Inhibitors. Antiviral Res. 1992, 17, 265-278.
9. Kempf, D. J.; Codacovi, L.; Wang, X. C.; Kohlbrenner, W. E.; Wideburg, N. E.; Saldivar, A.; Vasavanonda, S.; Marsh, K. C.; Bryant, P.; Sham, H. L.; Green, B. E.; Betebenner, D. A.; Erickson, J.; Norbeck, D. W. Symmetry-based Inhibitors of HIV Protease. Structure-Activity Studies of Acylated 2,4-Diamino-1,5-diphenyl-3-hydroxypentane and 2,5-Diamino-1,6-diphenylhexane-3,4-diol. J. Med. Chem. 1993, 36, 320-330.
10. Kempf, D. J.; Marsh, K. C.; Fino, L. C.; Bryant, P.; Craig-Kennard, A.; Sham, H. L.; Zhao, C.; Vasavanonda, S.; Kohlbrenner, W. E.; Wideburg, N. E.; Saldivar, A.; Green, B. E.; Herrin, T.; Norbeck, D. W. Design of Orally Bioavailable, Symmetry-based Inhibitors of HIV Protease. Bioorg. Med. Chem. 1994, 2, 847-858.
11. Kempf, D. J.; Marsh, K. C.; Denissen, J. F.; McDonald, E.; Vasavanonda, S.; Flentge, C. A.; Green, B. E.; Fino, L.; Park, C. H.; Kong, X.-P.; Wideburg, N. E.; Saldivar, A.; Ruiz, L.; Kati, W. M.; Sham, H. L.; Robins, T.; Stewart, K. D.; Hsu, A.; Plattner, J. J.; Leonard, J. M.; Norbeck, D. W. ABT-538 is a Potent Inhibitor of Human Immunodeficiency Virus Protease and has High Oral Bioavailability in Humans. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2484-2488.
12. Vacca, J. P.; Dorsey, B. D.; Schleif, W. A.; Levin, R. B.; McDaniel, S. L.; Darke, P. L.; Zugay, J.; Quintero, J. C.; Blahy, O. M.; Roth, E.; Sardana, V. V.; Schlabach, A. J.; Graham, P. I.; Condra, J. H.; Gotlib, L.; Holloway, M. K.; Lin, J.; Chen, I.-W.; Vastag, K.; Ostovic, D.; Anderson, P. S.; Emini, E. A.; Huff, J. R. L-735,524: An Orally Bioavailable Human Immunodeficiency Virus Type 1 Protease Inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 4096-4100.
13. Lam, P. Y.-S.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N.; Chang, C.-H.; Weber, P. C.; Jackson, D. A.; Sharpe, T. R.; Erickson-Vitanen, S. Rational Design of Potent Bioavailable, Non-peptide Cyclic Urea as HIV Protease Inhibitors. Science 1994, 263, 380-384.
14. Wong, Y. N.; Burcham, D. L.; Saxton, P. L.; Erickson-Vitanen, S.; Grubb, M. F.; Quon, C. Y.; Huang, S.-M. A Pharmacokinetic Evaluation of HIV Protease Inhibitors, Cyclic Ureas, in Rats and Dogs. Biopharm. Drug Disp. 1994, 15, 535-544.
15. Getman, D. P.; DeCrescenzo, G. A.; Heintz, R. M.; Reed, K. L.; Talley, J. J.; Bryant, M. L.; Clare, M.; Houseman, K. A.; Marr, J. J.; Mueller, R. A.; Vazquez, M. L.; Shieh, H.-S.; Stallings, W. C.; Stegeman, R. A. Discovery of a Novel Class of Potent HIV-1 Protease Inhibitors Containing the (R)-(Hydroxyethyl)urea Isostere. J. Med. Chem. 1993, 36, 288-291.
16. Bryant, M. HIV Protease Inhibitors: Action to Efficacy. Inhibitor SC-55389a presented at Session 46 (I) at the 34th ICAAC, Orlando, FL, 1994.
17. Kim, E. E.; Baker, C. T.; Dwyer, M. D.; Murcko, M. A.; Rao, B. G.; Tung, R. D.; Navia, M. A. Crystal Structure of HIV-1 Protease in Complex with VX-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme. J. Am. Chem. Soc. 1995, 117, 1181-1182.
18. Kaldor, S. W.; Kalish, V. J.; Davies, J. F.; Shetty, B. V.; Fritz, J. E.; Appelt, K.; Burgess, J. A.; Campanale, K. M.; Chirgadze, N. Y.; Clawson, D. K.; Dressman, B. A.; Hatch, S. D.; Kahalil, D. A.; Kosa, M. B.; Lubbehusen, P. P.; Muesing, M. A.; Patick, A. K.; Su, K. S.; Tatlock, J. H. AG1343, A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease. Submitted for publication in J. Med. Chem.
19. Mimoto, T.; Imai, J.; Kisanuki, S.; Enomoto, H.; Hattori, N.; Akaju, K.; Kiso, Y. Kynostatin KNI-227 and -272, Highly Potent Anti-HIV Agents: Conformationally Constrained Tripeptide Inhibitors of HIV Protease Containing Allophenylnorstatine. Chem. Pharm. Bull. 1992, 40, 2251-2253.
20. Thaisrivongs, S.; Tomich, P. K.; Watenpaugh, K. D.; Chong, K.-T.; Howe, W. J.; Yang, C.-P.; Strohbach, J. W.; Turner, S. R.; McGrath, J. P.; Bohanon, M. J.; Lynn, J. C.; Mulichak, A. M.; Spinelli, P. A.; Hinshaw, R. R.; Pagano, P. J.; Moon, J. B.; Ruwart, W. J.; Wilkinson, K. F.; Rush, B. D.; Zipp, G. L.; Dalga, R. J.; Schwende, F. J.; Howard, G. M.; Padbury, G. E.; Toth, L. N.; Zhao, Z.; Koeplinger, K. A.; Kakuk, T. J.; Cole, S. L.; Zaya, R. M.; Piper, R. C.; Jeffrey, P. Structure-Based Design of HIV Protease Inhibitors: 4-Hydroxycoumarins and 4-Hydroxy-2-pyrones as Non-peptidic Inhibitors. J. Med. Chem. 1994, 37, 3200-3204.
21. Skulnick, H. I.; Johnson, P. D.; Howe, W. J.; Tomich, P. K.; Chong, K.-T.; Watenpaugh, K. D.; Janakiraman, M. N.; Dolak, L. A.; McGrath, J. P.; Lynn, J. C.; Horng, M.-M.; Hinshaw, R. R.; Zipp, G. L.; Ruwart, M. J.; Schwende, F. J.; Zhong, W.-Z.; Padbury, G. E.; Dalga, R. J.; Shiou, L.; Possert, P. I.; Rush, B. D.; Wilkinson, K. F.; Howard, G. M.; Toth, L. N.; Williams, M. G.; Kakuk, T. J.; Cole, S. L.; Zaya, R. M.; Thaisrivongs, S.; Aristoff, P. A. Structure-Based Design of Sulfonamide Substituted Non-peptidic HIV Protease Inhibitors. J. Med. Chem. 1995, 38, 4968-4971.
22. Bourinbaiar, A. S.; Tan, X.; Nagorny, R. Effect of the Oral Anticoagulant, Warfarin, on HIV-1 Replication and Spread. AIDS 1993, 7, 129-130.
23. Tummino, P. J.; Ferguson, D.; Hupe, L.; Hupe, D. Competitive Inhibition of HIV-1 Protease by 4-Hydroxy-benzopyran-2-ones and by 4-Hydroxy-6-phenylpyran-2-ones. Biochem. Biophys. Res. Commun. 1994, 200, 1658-1664.
24. Tummino, P. J.; Ferguson, D.; Hupe, D. Competitive Inhibition of HIV-1 Protease by Warfarin Derivatives. Biochem. Biophys. Res. Commun. 1994, 201, 290-294.
25. Vara Prasad, J. V. N.; Para, K. S.; Lunney, E. A.; Ortwine, D. F.; Dunbar, Jr., J. B.; Ferguson, D.; Tummino, P. J.; Hupe, D.; Tait, B. D.; Domagala, J. M.; Humblet, C.; Bhat, T. N.; Liu, B.; Guerin, D. M. A.; Baldwin, E. T.; Erickson, J. W.; Sawyer, T. K. Novel Series of Achiral, Low Molecular Weight, and Potent HIV-1 Protease Inhibitors. J. Am. Chem. Soc. 1994, 116, 6989-6990.
26. Lunney, E. A.; Hagen, S. E.; Domagala, J. M.; Humblet, C.; Kosinski, J.; Tait, B. D.; Warmus, J. S.; Wilson, M.; Ferguson, D.; Hupe, D.; Tummino, P. J.; Baldwin, E. T.; Bhat, T. N.; Liu, B.; Erickson, J. W. A Novel Nonpeptide HIV-1 Protease Inhibitor: Elucidation of the Binding Mode and Its Application in the Design of Related Analogs. J. Med. Chem. 1994, 37, 2664-2677.
27. Wlodawer, A.; Erickson, J. W. Structure-based Inhibitors of HIV-1 Protease. Annu. Rev. Biochem. 1993, 62, 543-585.
28. Appelt, K. Crystal Structures of HIV-1 Protease-Inhibitor Complexes. Perspect. Drug Discovery Des. 1993, 1, 23-48.
29. Thaisrivongs, S.; Watenpaugh, K. D.; Howe, W. J.; Tomich, P. K.; Dolak, L. A.; Chong, K.-T.; Tomich, C.-S. C.; Tomasselli, A. G.; Turner, S. R.; Strohbach, J. W.; Mulichak, A. M.; Janakiraman, M. N.; Moon, J. B.; Lynn, J. C.; Horng, M.-M.; Hinshaw, R. R.; Curry, K. A.; Rothrock, D. J. Structure-Based Design of Novel HIV Protease Inhibitors: Carboxamide-Containing 4-Hydroxycoumarins and 4-Hydroxy-2-pyrones as Potent Nonpeptidic Inhibitors. J. Med. Chem. 1995, 38, 3624-3637.
30. Romines, K. R.; Watenpaugh, K. D.; Howe, W. J.; Tomich, P. K.; Lovasz, K. D.; Morris, J. K.; Janakiraman, M. N.; Lynn, J. C.; Horng, M.-M.; Cong, K.-T.; Hinshaw, R. R.; Dolak, L. A. Structure-Based Design of Nonpeptidic HIV Protease Inhibitors from a Cyclooctylpyranone Lead Structure. J. Med. Chem. 1995, 38, 4463-4473.
31. n′ refer to the nomenclature for enzyme binding pockets as described in Schechter, I.; Berger, A. On the Size of the Active Site in Proteases. I. Papain. Biochem. Biophys. Res. Commun. 1967, 27, 157-162.
32. Unpublishee result in the cyclooctylpyranone series (Aristoff, P. A.).
33. Mulichak, A. M.; Hui, J. O.; Tomasselli, A. G.; Heinrikson, R. L.; Curry, K A.; Tomich, C.-S.; Thaisrivongs, S.; Sawyer, T. K.; Watenpaugh, K. D. The Crystallographic Structure of the Protease from Human Immunodeficiency Virus Type 2 with Two Synthetic Peptide Transition State Analog Inhibitors. J. Biol. Chem. 1993, 268, 13103-13109.
34. Howard, A. J.; Gilliland, G. L.; Finzel, B. C.; Poulos, T. L.; Ohlendorf, D. H.; Salemme, F. R. The Use of an Imaging Proportional Counter in Macromolecular Crystallography. J. Appl. Crystallogr. 1987, 20, 383-387.
35. Tomasselli, A. G.; Howe, W. J.; Sawyer, T. K.; Wladawer, A.; Heinrikson, R. L. The Complexities of AIDS: An Assessment of the HIV Protease as a Therapeutic Target. Chim. Oggi 1991, 9, 6-27.
36. Hendrickson, W. A.; Konnert, J. H. Stereochemically Restrained Crystallographic Least-squares Refinement of Macromolecule Structures. In Biomolecular Structure, Function and Evolution; Srinivasan, R., Ed.; Pergamon Press: Oxford, 1980; pp 43-57.
37. Sack, J. S. CHAIN: a Crystallographic Modelling Program. J. Mol. Graphics 1988, 6, 224-225.
38. Hall, S. R., Stewart, J. M., Eds. Xtal 3.0 Reference Manual; Universities of Western Australia, Perth and Maryland: College Park, MD, 1990.
39. Watenpaugh, K. D. Conformational Energy as a Restraint in Refinement. In Proceeding of the Molecular Dynamics Workshop, 1984, Chapel Hill; Hermans, J., Ed.; Polycrystal Book: Western Springs, IL, 1985; pp 77-80.
40. Bernstein, F. C.; Koetzle, T. F.; Williams, G. J. B.; Meyer, E. F.; Brice, M. D.; Rogers, J. B.; Kennard, O.; Shimanouchi, T.; Tasumi, M. The Protein Data Bank: A Computer-based Archival File for Macromolecular Structures. J. Mol. Biol. 1977, 112, 535-542.
41. Tomasselli, A. G.; Olsen, M. K.; Hui, J. O.; Staples, D. J.; Sawyer, T. K.; Heinrikson, R. L.; Tomich, C.-S. C. Substrate Analogue Inhibition and Active Site Titration of Purified Recombinant HIV-1 Protease. Biochemistry 1990, 29, 264-269.
42. Mossmann, T. Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays. J. Immunol. Methods 1983, 65, 55-63.
43. Chong, K.-T.; Pagano, P. J.; Hinshaw, R. R. Bisheteroarylpiperazine Reverse Transcriptase Inhibitor in Combination with 3′-Azido-3′-Deoxythymidine or 2′,3′-Dideoxycytidine Synergistic Inhibits Human Immunodeficiency Virus Type 1 Replication In Vitro. Antimicrob. Agents Chemother. 1994, 38, 288-293.